N/A Completed N=25 Randomized Supportive Care

Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis

Osteoarthritis

Source: ClinicalTrials.gov NCT00682357 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2016

Primary outcomePrimary: Change in Serum Osteocalcin — -2.18; -0.45; -1.10 ng/mL

Summary

Oral and nasal steroids may enhance osteoporosis by suppressing bone formation. Intra-articular steroids may also suppress bone formation, however, the duration or relationship to a steroid dose has not been established. It is hypothesized that intra-articular steroids suppress bone formation transiently, returning to pretreatment levels within four weeks in subjects with osteoarthritis.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Serum Osteocalcin	-2.18; -0.45; -1.10	—
PRIMARY Change in Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b)	-0.153; -0.295; -0.148	—
SECONDARY Change in Testosterone	0.08	—
SECONDARY Change in Serum Cortisol	-1.16; 0.65; 1.30	—

Eligibility Criteria

Inclusion Criteria

Age > 40 years
Male or postmenopausal female
Diagnosis of knee osteoarthritis
DEXA bone density done within the past 12 months
Painful knee, visual analogue scale (VAS) > 4 of (10=worst)

Exclusion Criteria

Diabetes Mellitus Type I or II
Systemic inflammatory illness
Systemic infections which may be aggravated by steroid therapy
No current or previous (< 3 years) biphosphate therapy
Previous knee replacement surgery
No current or previous Parathyroid hormone (PTH) therapy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00682357). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.